The Role of Biomarker Testing in Advanced NSCLC
Science & Innovation Webinar
Webinar Recorded on Sep. 27, 2021
Sponsored by EMD Serono
NCCN Clinical Practice Guidelines in Oncology recommends testing for certain molecular and immune biomarkers in all appropriate patients with metastatic NSCLC to assess whether patients are eligible for targeted therapies or immunotherapies based on data showing improvement in overall survival for patients receiving targeted therapies or immunotherapies compared with traditional chemotherapy regimens. Although biomarker testing rates have increased in the last few years, challenges to biomarker testing in non-small cell lung cancer remain. In this webinar, Dr. Paul Paik, an expert who has deep knowledge of and experience in biomarker testing and treating NSCLC patients will discuss the importance of biomarker testing for metastatic non-small cell lung cancer. It is critical to create awareness on the importance of biomarker testing for healthcare providers to not only help identify potentially efficacious targeted therapies for patients but also to identify therapies unlikely to provide clinical benefit.
- Paul Paik, MD
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.